1 A QUESTION OF BALANCE: DEALING FAIRLY WITH CLAIMS FOR MEDICINES Peter Folb Treatment Action Campaign 26 September 2006.

Slides:



Advertisements
Similar presentations
Project Quality Plans Gillian Sandilands Director of Quality
Advertisements

The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Research Within The NHS Prof Alison MacLeod Director Research & Development.
Definitions of EBP Popular in SW
London Medicines Information Service (Northwick Park Hospital) - June 2008 Drug Promotion: The Pharmaceutical Representative. Making the most of Promotional.
5th Annual PBM Pharmacy Informatics Conference
ROLE OF THE PHYSICIAN IN THE APPROVAL PROCESS Stephanie de Bono MD PhD Medical Advisor, Eli Lilly.
Introduction to Drug Information Services Ch.#1. An introductory course to teach the students basic principles of DI retrieval. Designed to help students.
© IPA 2011 Governance Challenges in Healthcare Aidan Horan Institute of Public Administration 2 nd June 2011.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
What Do Toxicologists Do?
Personnel Basic Principles of GMP Workshop on
AND GENERIC DRUGS BRAND-NAME AND GENERIC DRUGS WHAT TO CHOOSE? Natalia VEZIKOVA, MD, PhD, Natalia VEZIKOVA, MD, PhD, MSc The Head of the Hospital Therapy.
Clinical Pharmacy Basma Y. Kentab MSc..
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Whilst the pharmaceutical industry plays a key role in developing and producing medicines, there is a tension between industry’s need to expand product.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Interoperability to Support a Learning Health System HL7 Learning Health Systems Workgroup.
New Zealand Medicines and Medical Devices Safety Authority A business unit of the Ministry of Health.
Community Issues And Needs Associated With Microbicides Clinical Trials Presenter: John M. Mutsambi, Community Liaison Officer with University of Zimbabwe.
For more information…. Traditional Healing, Research and Development Presentation for the Portfolio Committee on Arts, Culture, Science and Technology.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
NICE Decision Making Dr Katherine Payne North West Genetics Knowledge Park The University of Manchester
Medicines for Children Research Network Paediatric Clinical Trials: Principles, Practicality and the Medicines for Children Research Network Andrew Collinson.
Stefan Franzén Introduction to clinical trials.
INTRODUCTION TO RA.
DRUG DEVELOPMENT & REGULATIONS DR ARIF HASHMI. DRUG DEVELOPMENT Discovery and synthesis Preclinical development (chemical testing, biological testing,
Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.
SAHPRA proposals Nov 2009 A GLIMPSE OF WHAT SAHPRA IS INTENDED TO BECOME KEY PROPOSALS FOR SAHPRA NOVEMBER 2009 DR NICHOLAS CRISP.
Supporting Informed Formulary Decision Making: CADTH’s Common Drug Review Denis Bélanger, Director, CADTH New Brunswick Stroke Summit November 27, 2010,
TERRENCE F. ACKERMAN, PH.D. PROFESSOR OF BIOETHICS CHAIR, UTHSC IRB.
“USAPI-PHARMACY ASSOCIATION - RESPONSE TO NCD ROADMAP” Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa 51 st 1-18 nov 2011 Evelyn Ahhing-Faaiuaso RPH PHARMD Pihoa.
“What’s in it for us?” NICE Guideline: Safe and Effective use of Medicines (Medicines Optimisation) Erin Whittingham Public Involvement Adviser Public.
$100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 $100 $200 $400 $500 $300 Terms Clinical Trial Facts.
Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.
FDA Draft Guidance Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Strategic Objective 4 To promote the exchange of experiences and regulatory knowledge between NRAs inside and outside PANDRH“ Lessons learned from international.
The First Conference for Medicines Regulatory Authorities In Sudan and Neighboring Countries Khartoum December 2014 Alain PRAT, Technical Officer,
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
Rene Descartes: “I think; therefore I am.”. 3.3: Data Ethics Statistics Chap 3: Designing Experiments.
Compassionate use programs and the European regulatory system Filip Josephson M.D., Ph.D. Clinical Assessor.
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
PHARMA HELPLINE SOCIETY we care,we assist, we help Announces on line courses for the overall development of pharmacy professionals and students. These.
A capacity building programme for patient representatives
Efficacy and Safety of Medicines
MEP Interest Group on Brain, Mind and Pain
Health Technology Assessment
International Association of Tax Judges
FDA Perspective on Cardiovascular Device Development
Community Participation in Research
8. Causality assessment:
How to Apply for and Receive Industry Funding for Investigator Sponsored Research Chuck Simonton MD, FACC, FSCAI Chief Medical Officer Abbott Vascular.
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Within Trial Decisions: Unblinding and Termination
The WHO Prequalification of Medicines Programme Capacity building agenda Dr Milan Smid.
Dr Samvel Azatyan Technical Officer Regulatory Support
Ethical Principles of Research
Jordan Food & Drug Administration
International Association of Tax Judges
Effective Quality Assurance in Healthcare, Kyrgyzstan
Issues in Hypothesis Testing in the Context of Extrapolation
External Examiner Reports
WHO’s Role in Assuring the Quality Safety and Efficacy of Drugs:
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Qualified persons of pharmaceutical manufacturers
Approach: The Cuban Regulatory Strategy
Presentation transcript:

1 A QUESTION OF BALANCE: DEALING FAIRLY WITH CLAIMS FOR MEDICINES Peter Folb Treatment Action Campaign 26 September 2006

2 CONSIDERING CLAIMS Quality Efficacy Safety - In the public interest Note: Need clause National Regulatory Authority (NRA)

3 EXPERTISE REQUIRED BY NRA Clinical medicine Paediatrics Toxicology Clinical pharmacology Pharmacology Pharmacy and industrial pharmaceutics Statistics and epidemiology Public health

4 ALL DECISIONS OF THE NRA MUST BE in the public interest free of external influence without fear or favour based on strict scientific and clinical evidence explicable to applicant and public

5 SPECIAL ISSUES locus standi audi alteram partem subject to appeal mandamus NOTES: SA ADMINISTRATIVE LAW CONFIDENTIALITY

6 INVOLVEMENT OF THE PUBLIC Risk – benefit assessment Conferring with the public Accounting to the public Rules for limiting advertisement NB: Government is an ordinary client – manufacture; advocacy role Encouraging public self- sufficiency Encouraging public self- sufficiency

7 TRADITIONAL MEDICINES – SPECIAL ISSUES Empirical nature of practice International pharmacopoeias Quality – Good Manufacturing Practice Safety – normal standards Efficacy – no misleading claims SETTING SCIENTIFIC STANDARDS

8 WORKING WITH THE HEALERS SA Novel Drugs Development Programme TB; malaria; diabetes; immune modulation Innovation Fund award Clinical trials (Note: ethics) Agricultural processing SETTING NEW STANDARDS OF COLLABORATION

9 WHO EVALUATION OF NRA Statutory basis for evaluation Quality systems for each NRA function Independence in decision-making Effective recall system Appropriate expertise and qualification of staff NRA institutional development plan Transparency and public accountability